Catalyst
Slingshot members are tracking this event:
FDA Approves Expanded Indication for Merck’s KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma; KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 18, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Melanoma, Fda, Aproval, Keytruda, Pembrolizumab
